【ChiCTR2100044824】Minimally invasive hook-assisted reduction and cephalomedullary nailing for intertrochanteric femur fractures
ChiCTR2100044824
结束
/
/
/
2021-03-27
/
/
Intertrochanteric femur fracture
Minimally invasive hook-assisted reduction and cephalomedullary nailing for intertrochanteric femur fractures
Minimally invasive hook-assisted reduction and cephalomedullary nailing for intertrochanteric femur fractures
73200
In IFFs, it is necessary to anatomically reduce the medial hinge to perform stable osteosynthesis with an intramedullary implant. The displacement of broken fragments by strong muscles may not allow the fracture to be closed. In this study, it was aimed to evaluate hook-assisted reduction used in patients with IFFs used when reduction was difficult or the reduction provided was lost. Our hypothesis was that minimally invasive hook-assisted reduction would reduce surgical time and radiation exposure, and also improve radiologic results.
析因分组（即根据危险因素或暴露因素分组）
回顾性研究
All patients who have appropriate follow up were included thus no randomization procedure was performed.
N/A
No
/
32;28
/
2019-09-24
2020-08-26
/
Between December 2015 and March 2019, 66 patients with IFFs who underwent osteosynthesis with cephalomedullary nailing were identified. One patient died in the early postoperative period, and five patients did not attand outpatient follow after being discharged. Accordingly, 60 patients were included in this study and evaluated retrospectively.；
请登录查看Patients were excluded if they had A1.1 type proximal femur fractures, collo-diaphyseal angle distortion less than 5 degrees from the opposite side, patients under 18 years, injuries present in the ipsilateral lower limb, patients with pathologic fractures, patients with follow-up less than 6 months, patients undergoing arthroplasty, and fractures fixed with implants other than intramedullary nails.；
请登录查看namik kemal university health hospital
59100
namik kemal university health hospital的其他临床试验
土耳其Cizre state hospital, Sirnak state, Turkey的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29